Back to Atlas
BSemi-durableStandard research/education caution
CMP-0701
Research chemical/reference listing
Veldoreotide
GH/IGF axis / recovery
Recovery, body composition, and anabolic signaling support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- GH/IGF-axis peptide
- Primary mechanism
- Growth hormone / IGF pathway modulation
- Primary market use
- GH/IGF axis / recovery
Pharmacology
- Molecular weight (Da)
- 1123.30
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5 . Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide ( HY-P0036 ). Veldoreotide has the potential to be used as pain modulating agent